Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.

doi:10.3109/0284186X.2014.969846

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.

Acta oncologica (Stockholm, Sweden) - 1 Apr 2015

Eckhoff Lise, Feddersen Søren, Knoop Ann S, Ewertz Marianne, Bergmann Troels K

Abstract excerpt

BACKGROUND: Docetaxel is a highly effective treatment of a wide range of malignancies but is often associated with peripheral neuropathy. The genetic variability of genes involved in the transportation or metabolism of docetaxel may be responsible for the variation in docetaxel-induced peripheral neuropathy (DIPN). The main purpose of this study was to investigate the impact of genetic variants in GSTP1 and ABCB1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Confidence Intervals
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Epirubicin

Share to Glutathione S-Transferase pi

Share to Peripheral Nervous System Diseases

Share to Taxoids

Source

Open in PubMed

Identifiers

PMID: 25383449
DOI: 10.3109/0284186X.2014.969846

Genes

GSTP1
ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.